GH Optimization Stack

What Is the GH Optimization Stack?

The GH Optimization Stack pairs two lab-made peptides, CJC-1295 and Ipamorelin, that each nudge the body’s own growth hormone (GH) release through different receptors. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH), while Ipamorelin is a selective ghrelin-receptor agonist, a class often called a growth hormone secretagogue (GHS). Because they act on separate receptors within the same GH-IGF-1 pathway, users and some prescribers pair them with the goal of a larger, more sustained pulse of GH and downstream insulin-like growth factor 1 (IGF-1) than either peptide would produce alone.

How It’s Proposed to Work

GHRH analogs like CJC-1295 signal the pituitary gland to release GH, while ghrelin-receptor agonists like Ipamorelin amplify that release and suppress somatostatin, the hormone that normally restrains GH secretion. Elevated GH raises circulating IGF-1, a hormone associated with tissue repair, lean-mass maintenance, and metabolic changes, which is the underlying rationale for using this combination for recovery and body-composition goals.

What the Research Shows

This is one of the better-documented peptide pairings on this site, because each half has its own published human data. We have not located a published human trial that tests CJC-1295 and Ipamorelin together as a stack, or that measures sports-recovery or physique outcomes for either peptide individually.

• Teichman et al. · Journal of Clinical Endocrinology & Metabolism, 2006

  Sustained GH and IGF-1 Elevations After a Single Dose

  A 2006 randomized clinical trial gave healthy adults CJC-1295 and measured sustained elevations in GH and IGF-1 lasting days after a single dose.

  Read the study on PubMed →
• Beck et al. · 2014

  Postoperative Ileus Trial (Bowel-Resection Patients)

  Ipamorelin has its own controlled human trial, though not for athletic recovery: a randomized, placebo-controlled study in bowel-resection patients tested it for postoperative ileus and found a modest, statistically non-significant improvement in time to first tolerated meal.

  Read the study on PubMed →
• Dominikowski et al. · Frontiers in Endocrinology, 2026

  Comprehensive Review of GH-IGF-1 Peptides in Self-Administered Protocols

  A comprehensive June 2026 review surveys this entire category of GH-IGF-1 peptides used in self-administered protocols and is worth reading in full before starting a regimen; it catalogs reported adverse effects such as elevated prolactin and cortisol, fluid retention, joint and muscle pain, and injection-site reactions, and notes that human evidence for performance or recomposition claims ranges from limited to entirely absent depending on the compound.

  Read the study on PubMed →
• Dominikowski et al. · Front Endocrinol, 2026

  GH-IGF-1 Axis Peptides: Evidence Tiers & Safety

  A June 2026 review in Frontiers in Endocrinology maps GHRH analogues and secretagogues — including CJC-1295 (with and without DAC) and ipamorelin — onto evidence tiers ranging from trial-grade data to no human studies, and catalogues reported endocrine, metabolic and fluid-retention adverse effects.

  Read the review on PubMed →

Regulatory & Safety Status You Should Know

The two halves of this stack currently sit in different regulatory positions, which is worth understanding before combining them.

Neither peptide is FDA-approved for GH optimization, athletic recovery, or anti-aging use; the only FDA-approved GH-axis drugs are prescribed for specific diagnosed conditions such as GH deficiency. Anyone considering this stack should get baseline and follow-up bloodwork, including IGF-1, prolactin, cortisol, and glucose, through a licensed clinician rather than a supplier, given the endocrine effects both compounds are designed to produce.

July 2026 compounding update: The FDA’s Pharmacy Compounding Advisory Committee met on July 23–24, 2026 and recommended several peptides (including BPC-157, TB-500, KPV and MOTS-c) for the Section 503A compounding list. Growth-hormone secretagogues such as CJC-1295 and ipamorelin were not among the substances reviewed or recommended at that meeting, and their regulatory status is unchanged by it — they remain unapproved for human use.

Our Commitment to Credibility

We link every claim above to its primary source, note where each peptide’s regulatory status differs, and revisit this page as new studies or regulatory decisions publish. If you are considering this stack, discuss it with a licensed physician, request bloodwork, and check the FDA’s current list before sourcing either peptide through any pharmacy.